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High dose vitamin C supplement use is associated with a history of cancer and 
other illnesses in the UK Women’s Cohort Study 
Abstract (Words 250) 
Objective: To determine whether regular vitamin C supplement use is associated with healthier 
behaviours, and a history of cancer and other illness in UK women. 
 Design: This cross-sectional analysis examines the odds of taking supplements containing 
vitamin C as recorded in 4-day food diaries, based on lifestyle characteristics and morbidity 
history self-reported by questionnaire. 
Subjects: 12,453 middle-aged women from the UK Women’s Cohort Study (UKWCS).  
Results: Women regularly taking supplements containing vitamin C, compared to those than did 
not, had healthier behaviours, including higher consumption of fruit and vegetables. Regular 
high dose vitamin C takers (>=1000mg) had a higher socioeconomic status, visited alternative 
practitioners more often than family or private doctors, and were more likely to be ex-smokers, 
and to drink little or no alcohol. Women with a self-reported personal or family history of cancer 
had increased odds of being regular high dose users ((OR=1.33 (95% CI: 1.00, 1.76) and 
OR=1.16 (95% CI: 0.95, 1.41) respectively after adjusting for socio-demographic and health 
behaviours). Specifically, high dose vitamin C taking was significantly associated with personal 
(OR=1.70 (95% CI: 1.14, 2.55)) or family (OR=1.26 (95% CI: 1.01, 1.58)) history of breast 
cancer. Women with personal or family histories of some cardiovascular or intestinal disorders 
were more likely to take supplements containing vitamin C, though not necessarily at high doses.  
Conclusion: High dose vitamin C taking by UK women was associated with healthier behaviours 
and a history of breast cancer, total cancer and other illnesses. Patient guidelines for their use 
may be needed. 
Introduction 
Despite lack of evidence of benefits, vitamin supplement-taking reported by UK women 
increased from 17% in 1986/1987 to 41% reported in 2008/9
(1,2)
.  Users are most likely to be 
women above 55yrs and of higher socioeconomic status
(3)
. An analysis of the UK Women’s 
Cohort Study (UKWCS) found that users were significantly more likely to lead healthier 
lifestyles: to be more physically active; have a lower alcohol intake; a lower body mass index 
(BMI) and eat diets which met recommended dietary intakes. Therefore they were less likely to 
need supplements than non-users
(4)
. Further support for this ‘inverse supplement hypothesis’ has 
been found in the UK
(2,5,6)
, and elsewhere
(7-12)
. Moreover, those classifying themselves as high 
strength supplement users in a recent UK survey were particularly health conscious
(3)
. 
Vitamin C is one of the most commonly used supplements in the UK
(3,13)
. However, suggestions 
that it is able to reduce the incidence of colds, have been unsubstantiated in randomised 
controlled trials
(14,15)
. Furthermore, despite clear evidence of an association between plasma 
vitamin C levels and reduced mortality from all-causes, from cardiovascular disease, and from 
ischemic heart disease
(16)
, there is limited evidence to suggest that vitamin C supplement-taking 
is associated with reduced risk of chronic diseases
(17)
.  
Although general supplement use is particularly widespread in cancer survivors in the US, with 
breast cancer survivors showing the highest use
(18)
, no overall association between vitamin C 
supplement-taking (>=150mg) and prevalent cancer was found in the US Vitamins and Lifestyle 
(VITAL) cross-sectional study
(19)
. Furthermore those with pre-existing diabetes, hypertension, 
cardiovascular disease (CVD) were less likely to use them
(19)
. However, a US study of women 
physicians showed those with pre-existing breast cancer were more likely to take vitamin C 
supplements than breast cancer free women
(8)
. 
UK health-conscious cancer survivors were also more likely to take any supplement than cancer 
free women
(13)
; however, other pre-existing chronic diseases have been inversely associated with 
taking vitamins, minerals or antioxidants in a UK study combining men and women
(5)
.
  
To the 
best of our knowledge no study has examined the relationship between vitamin C supplement-
taking in UK women and lifestyle factors or personal or family history of morbidities. Our study 
capitalises on the large sample size of the UKWCS, substantial numbers of women regularly 
taking vitamin C (34%) and the wide variety of characteristics and self-reported illnesses 
recorded. The main aims of the study were to determine whether vitamin C supplement-taking in 
the UKWCS was associated with healthier behaviours, and whether women with a history of 
cancer, in particular breast cancer, were more likely to use them. 
Methods
 
UKWCS recruitment data was gathered between1995-1998 from 35,367 women who completed 
a 217-item Food frequency questionnaire (FFQ)
(20-22)
. This national cohort of mainly caucasian, 
well-educated, middle-class, middle-aged, married women was designed to compare disease 
incidence in vegetarians, fish-eaters and meat-eaters
(20)
. At recruitment 62% of participants took 
some type of dietary supplement.   
Two to five years after recruitment, all the initial participants were re-contacted and 12,453 
(35%) completed a follow-up questionnaire and a 4-day food diary. For each day, the diaries 
requested supplement brand, name, amount taken and dosage of any supplement taken. This 
information was matched against a database of supplement descriptions and ingredient 
composition obtained from product labels provided by participants, suppliers’ websites or 
provided directly from manufacturers. The average daily vitamin C intake contained in all 
supplement types was calculated for the total number of diary days vitamin C was taken. 
Using Stata version 10, unvariable logistic regression was applied to determine which participant 
characteristics predicted regular supplement-taking in two different classifications of users: those 
taking any dose of vitamin C (y/n); and those taking high doses of vitamin C (>=1000mg, y/n). 
These were compared to women not regularly taking ‘any’ or ‘high’ doses respectively. This 
high dose of 1000mg/day is the recommended safe upper limit; intakes at this level and above 
have been linked to adverse effects, particularly gastrointestinal disturbance
(23)
. This level is 
more than 15 times the recommended daily allowance (EU RDA = 60mg/day
(24)
) normally found 
in multivitamins.  Regular taking in this study was defined as taking on at least three out of the 
four diary days. Diary recording of doses >=90mg taken at this frequency showed substantial 
agreement with responses to daily vitamin C use reported on a separate questionnaire. Socio-
demographic and health related lifestyle variables that were significantly associated with either 
any dose or high intake were all included in a logistic regression model for mutual adjustment. 
Table 1 shows the categorisation of continuous and discrete variables and also displays the 
significance for trend values. 
Social class and marital status variables used information gathered by questionnaire at 
recruitment. All other variables were taken from responses to the follow-up questionnaire: BMI 
(kg/m
2
); smoking status; level of physical activity; parity; drinking alcohol less than once a 
week, red meat portions; total fruit and vegetable portions; frequency of visits to doctors and 
alternative practitioners. Vigorous activity was defined as activity causing shortness of breath, 
rapid heart rate and sweating. Attendance at routine health checks was not significantly 
associated with vitamin C taking, therefore was excluded from the models. 
These variables, excluding visits to doctors and alternative practitioners, were used in logistic 
regression analyses to adjust the odds of women with a family or personal history of cancers and 
other health problems taking any or high doses (>=1000mg) of vitamin C. Personal and family 
histories of breast cancer and total cancers were the principle analyses. For these and personal 
histories of the other cancers additional analyses were performed at doses above or equal to 
250mg; 500mg; and 2000mg. Since vitamin C supplements are more likely to be taken in winter 
sensitivity analyses were performed to assess the robustness of results to weighting the analyses 
by the inverse of the probability of being sampled in each season. 
All information relating to family or personal history of cancers and other illnesses was reported 
by the participant at follow-up. They were asked whether or not family members (blood relatives 
only) ever had medical conditions listed (see table 4 for types provided) or ever had the 
following cancers: breast, skin, lung, colon and rectum, ovary, stomach, cervix, ovary, pancreas, 
or prostate.  The cancer history of first and second degree relatives was used to identify women 
potentially at raised or high risk of hereditary breast cancer. It was unknown whether affected 
relatives were on the same side of the family, therefore this could only approximate to the 
guidelines provided by the UK’s Nation Institute for Health and Clinical Excellence (NICE)(25).  
Participants were also asked to report their own history of disease, including whether they had 
previously been told they had a diagnosis of one of the cancers listed above. 
  
Results 
Thirty four percent (4242) of women regularly took supplements containing any dose of vitamin 
C, and 5% (579) regularly took high doses of 1000mg or more. Twenty seven percent (1165) of 
those regularly taking any dose and 52% (299) taking high doses of vitamin C took 4 or more 
types of supplements. Furthermore, 82% of users taking any dose and 86% of the high dose users 
took some type of supplement at recruitment, on average 4 years earlier.  
 After mutual adjustment, significant lifestyle predictors of regularly taking supplements 
containing either high dose or any dose of vitamin C were eating more than 5 portions of fruit 
and vegetables per day; eating less portions of red meat; and visiting an alternative practitioner 
more often than women not regularly taking these supplements (table 1). Odds of visiting an 
alternative practitioner  4 or more times in the last 12 months were substantially greater for high 
dose takers compared to any dose takers ((OR=2.84 (95% CI: 2.20, 3.66) vs OR=1.75 (95% CI: 
1.51, 2.03)).  Additionally, the odds of taking supplements containing any dose of vitamin C 
were significantly higher in women who were aged 45yrs or more; of intermediate social class; 
divorced; childless; exercised vigorously more than 3 times a week (OR=1.52 (95% CI: 1.23, 
1.8)); regular visitors to their GP; or leaner. Significant predictors of regular high dose taking 
were being an ex-smoker, when compared with never smokers (OR=1.25 (95% CI: 1.02, 1.53), 
drinking alcohol less than once a week (OR=1.37 (95% CI: 1.12, 1.67) and being of high socio-
economic status compared to low status (OR=1.45 (95% CI: 1.06, 2.00). 
 
Insert table 1 here 
 
Table 2 shows that, after adjustment, regular high dose taking of vitamin C remained 
significantly associated with a personal history of any cancer (OR=1.33 (95% CI: 1.00, 1.76))  
and any hormone related cancer (OR=1.68 (95% CI: 1.16, 2.43)); specifically breast cancer 
(OR= 1.70 (95% CI: 1.14, 2.55). Additionally, regular high dose taking was significantly greater 
for women with a family history of breast cancer (OR=1.26 (95% CI: 1.01, 1.58) and appeared 
more likely in women with a family history of any cancer (OR=1.16 (95% CI: 0.95, 1.41)), any 
hormone related cancer (OR=1.19 (95% CI: 0.98, 1.46)), and pancreatic cancer (OR=1.44 (95% 
CI: 0.94, 2.21)). Taking any dose of vitamin C was significantly associated with a family history 
of cancer of the uterus (OR=1.38 (95% CI: 1.10, 1.74)). These results were almost identical 
when the analysis was weighted to take into account differential sampling in each season.  
 
Table 3 shows that the odds of taking vitamin C increased with increasing dose above 500mg for 
women who had any family member with a history of breast cancer or who had a personal 
history of breast cancer e.g. OR=1.09 (95% CI 0.78, 1.52) at >=500mg, OR=1.70 (95% CI 1.14, 
2.55) at >=1000mg and OR=2.36(95% CI 1.00, 5.56) at intakes of 2000mg or above. A similar 
pattern occurs for those with a personal history of cancer of the uterus or cervix, and was seen in 
the total analyses of any cancer or any hormone related cancer. The small numbers of women in 
some of the categories, however, may have influenced the results. Although the odds of having a 
mother or sister with breast cancer or potentially being at raised risk of this cancer increased with 
increasing intake, these were not statistically significant.  
 
Insert table 2 here 
 
Insert table 3 here 
 
High dose takers also had greater odds of having a personal history of cardiovascular and 
intestinal disorders after adjustment (OR=1.27 (95% CI: 1.02, 1.59) & OR=1.25 (95% CI: 1.03, 
1.51) respectively). Specifically they had double the odds of angina (OR=2.05 (95% CI: 1.21, 
3.45) and an increased risk of having haemorrhoids (OR=1.26 (95% CI: 1.01, 1.56), irritable 
bowel syndrome (OR=1.27 (95% CI: 0.98, 1.64) and anal fissures (OR=1.41 (95% CI: 0.95, 
2.09). Generally vitamin C intake was not significantly associated with a family history of 
morbidities in Table 4, however high intake was significantly associated with a family history of 
high blood pressure (OR=1.30 (95% CI: 1.07, 1.57), and any vitamin C intake was significantly 
associated with a family history of high cholesterol (OR=1.16 (95% CI: 1.01, 1.33). The use of 
supplements containing any dose of vitamin C was significantly associated with both family and 
personal history of arthritis. Conversely, women with diabetes mellitus were less likely to take 
them. 
 
 
Insert table 4 here
Discussion 
The regular intake of supplements containing any dose or high doses of vitamin C in the 
UKWCS was associated with healthier lifestyle behaviours, and therefore supports the inverse 
supplement hypothesis, as seen in analyses of any supplement-taking in the UK or elsewhere
(5-
12)
.
 
 Women taking either high (>=1000mg per day) or any dose of vitamin C were more likely to 
consume greater than 5 portions of  fruit and vegetables, the main dietary source of vitamin C. 
This is consistent with evidence from studies of any supplement-taking
(4,5,10)
, and US studies of 
vitamin C supplement-taking
(7,10)
, and suggests that many high dose vitamin C takers are less 
likely to need them. Furthermore, in-line with US findings, UKWCS vitamin C takers were 
likely to eat less meat
(8)
. They also exercised vigorously more frequently, supporting previous 
research linking activity to supplement taking
(4-6,9-12)
. Distinguishing characteristics of high dose 
vitamin C takers in the UKWCS which were not significant predictors of any dose taking were 
being an ex-smoker, drinking alcohol less than once a week and being of high socio-economic 
status; these characteristics nevertheless have been positively associated with taking any type of 
supplement in other studies
(3,6)
.  Additionally, high dose vitamin C takers appeared to rely more 
on alternative practitioners rather than family or private doctors. Health behaviours associated 
with vitamin C supplement taking are likely to reduce health risks, therefore those behaviours 
identified should be considered for adjustment in longitudinal studies of risks
(10)
. 
Despite controversy surrounding evidence of benefits of high vitamin C supplementation for 
prolonged cancer survival
(26-28)
, our results show women with any type of cancer were more 
likely to be high dose vitamin C supplement-takers than women with no history of cancer. Since 
antioxidants can potentially reduce the effectiveness of anti-cancer drugs
(29,30)
 patients should be 
encouraged to discuss their supplement use with their doctors in order to avoid contraindications. 
For some cancer patients supplement use may be a coping behaviour and a way of taking 
control
(31,32)
. Similar health related behaviours may also occur in women with concerns about 
risk of developing cancer: for instance women who attended mammography have also been 
positively associated with supplement taking in the US
(10)
. Likewise, women attending UK breast 
screening clinics had similar characteristics to supplement takers in the UKWCS and wanted diet 
and exercise advice to be provided at these clinics
(33)
.  
To the best of our knowledge this is the first UK study to analyse associations between vitamin C 
supplement-taking and specific prevalent cancers, and therefore the first to report significant 
associations of regular high dose vitamin C taking (=>1000mg/day) in women with a personal or 
family history of breast cancer. This supports findings that US women physicians with breast 
cancer were more likely to take vitamin C
(8)
. Furthermore, our results show the odds of taking a 
vitamin C supplement increased at higher doses (>2000mg). However, whilst US research found 
that women at high risk of breast cancer and with inconclusive genetic test results were 
significantly more likely to take supplements, the increased odds of taking high doses of vitamin 
C in the UKWCS for women with increased risk of hereditary breast cancer or those having 
mothers or sisters with breast cancer were not significant
(34)
.  Our results may be due to low 
numbers and lack of power. In general, a history of non-hormone related cancer did not appear to 
be associated with vitamin C supplement-taking in the UKWCS, nevertheless associations with a 
personal history of cervical cancer remained significant at some doses after adjustments, 
including adjustment of socio-economic status which is known to be linked with this cancer
(35)
. 
In relation to cancer prevention, the 1997 World Cancer Research Fund (WCRF) report, issued 
several years before the initiation of the UKWCS follow-up, stated that diets high in fruit and 
vegetables probably protected against cancer of the pancreas, stomach and lung, and that fruit, 
vegetables and vitamin C possibly protected against cervical cancer
(36)
. Promotion of these 
findings could have influenced supplement-taking at the time despite the report stating that 
supplements were probably unnecessary and unhelpful for reducing cancer risk
(36)
. The recent 
WCRF 2007 report clearly states that supplements are not recommended for cancer 
prevention
(37)
. Indeed high doses of some supplements, including vitamin C may promote the 
initiation of cancer
(38)
, 
 
additionally the vitamin may exhibit different mechanisms at cancer 
initiation than at later stages
(39)
. Apart from family history of breast cancer and a moderate but 
non-significant association with a family history of pancreatic cancer our results indicate that UK 
women were probably not taking high vitamin C supplements as a preventative measure due to a 
family history of cancer in general. Since cancer of the pancreas has a poor diagnosis, women 
with this family history may have been more motivated to take high doses of vitamin C 
supplements.  
Due to the cross-sectional nature of the study the direction of cause and effect cannot be 
determined; it is unknown whether vitamin C has been taken to prevent or manage symptoms of 
disorders or whether vitamin C has caused them. For instance associations with irritable bowel 
syndrome (IBS) could have been caused by side effects of taking large doses of vitamin C
(40)
. 
However, the significant associations with IBS occurred at any dose of vitamin C, rather than 
high dose specifically; therefore a plausible explanation is that very health conscious women 
who take supplements may be prone to anxiety which might cause IBS.  
It is unknown why vitamin C supplements were taken by women in the UKWCS. Given that 
only 17% of UK supplement users are advised to take supplements by their health practitioner
(3)
, 
with many others taking advice from friends, family, books and magazines
(31,41)
, some health 
conscious UK women with chronic conditions may be self-treating with vitamin C. 
Alternatively, those with disorders may take supplements to feel better in general or to increase 
immune function rather than to treat a condition itself
(42)
. Despite inconsistent evidence relating 
to links between vitamin C supplementation and a reduction in coronary heart disease and 
hypertension
(43-45)
, US female physicians with hypertension have been found to regularly take 
vitamin C
(8)
. Conversely, another US study found cardiovascular disease risk factors were 
inversely associated with regularly taking vitamin C >=150mg/day. Similarly, women with 
diabetes in our study were less likely to take any dose of vitamin C; it is unknown whether the 
burden of diabetic medication deters supplement-taking or whether a lack of interest in health 
confounds the negative association.  
Limitations of the study include self-reporting of medical conditions and lack of information to 
determine whether these developed before or after regular vitamin C supplement-taking started. 
Supplement descriptions were also self-reported, and for only four days by diary, nevertheless 
substantial agreement was found between this and daily taking recorded by questionnaire. 
Although the number of years of taking was not collected, and no further diary follow-up was 
conducted, the majority of vitamin C users (81%) were taking a supplement of some type on 
average 4 years earlier at recruitment. Associations with taking any dose vitamin C, for instance 
with arthritis, were likely to reflect taking of multivitamins or antioxidant combinations which 
contain vitamin C. Whilst high vitamin C dose supplements were unlikely to contain other 
ingredients,
(12)
 our results show that consistent with other research,
(3)
 women taking high doses 
were highly likely to take other supplements. Therefore vitamin C use may be a marker for 
intake of other supplements. An additional problem was the wide variety of formulations of 
supplements taken which made coding difficult. 
Another limitation of our study is that UKWCS participants were more health conscious than the 
general population and therefore not representative of the whole UK population. Differences in 
characteristics between regular takers and non-regular takers in the UKWCS may not be as 
pronounced as that found in the general population.  
Our research may help to identify high dose users, such as ex-smokers, low alcohol drinkers and 
women with a history of breast cancer or other illnesses who could be educated about 
inconsistencies in evidence relating to suggested benefits, and about warnings relating to high 
strength supplements
(46)
.  Furthermore, patients should be encouraged to discuss their 
supplement-taking with their doctors to avoid contraindications
(29,30)
. Finally, additional research 
is needed to establish the effects of both supplement and dietary vitamin C intake on cancer 
initiation and development, as well as other illnesses.   
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Table 1 Characteristics associated with taking supplements containing any dose of vitamin C 
and taking supplements containing high doses of vitamin C (1000mg or above)    
 Any dose(y/n)  >=1000mg (y/n)  
Characteristics    OR(95% CI)
*
  P value OR(95% CI)
*
 P value 
Age (years)
†
     
<45    1  0.07 1 0.3 
45-54     1.20 (1.03, 1.41)  1.11 (0.81, 1.54)  
55-64      1.26 (1.07, 1.48)  0.85 (0.60, 1.20 )  
65 and above      1.23 (1.03, 1.47)
  
 0.91 (0.62, 1.34)  
Social class
†
     
High   1  0.1 1 0.04 
Intermediate    1.10 (1.01, 1.21 )  0.96 (0.78, 1.17)  
Low   1.07 (0.94, 1.22)
  
 0.69 (0.50, 0.94)  
Marital status
†
     
Married or living together   1  0.4 1 0.9 
Divorced/separated    1.31 (1.14, 1.51 )  1.25 (0.94, 1.66)  
Widowed       0.95 (0.78, 1.16 )  1.14 (0.72, 1.80)  
Single       0.86 (0.72, 1.03)
  
 0.88 (0.61, 1.28)  
Had children     
Yes    1  0.001 1  0.09 
No       1.24 (1.11, 1.39)  1.23 (0.97, 1.56)  
     
Body mass index  (BMI kg/m
2
)
 †
     
underweight  (<18)  1.03 (0.72, 1.46 )  1.07 (0.53, 2.15)  
normal  (18-24.99) 1  0.08 1 0.6 
overweight  (25-30)  0.90 (0.82, 0.99 )  0.87 (0.69, 1.09)  
Obese  (>30)
   
0.93 (0.80, 1.07)
  
 1.11 (0.81, 1.54)
  
 
Smoking status
†
     
Never smoked    1  0.4 1 0.02 
Ex, smoker    1.07 (0.98, 1.17 )  1.25 (1.02, 1.53)  
Current smoker     0.91 (0.75, 1.00)  1.19 (0.79, 1.81)  
     
Drinks alcohol more than once a week     
Yes 1 0.1 1 0.001 
No 1.07 (0.98, 1.17)  1.37 (1.12, 1.67)  
Physical activity
†
     
No weekly physical activity  1  <0.001 1 0.008 
Light moderate most weeks    1.16 (0.95, 1.41)  0.94 (0.60, 1.48)  
Vigorous 1-2/week      1.18 (0.96, 1.46)  0.98 (0.61, 1.57)  
Vigorous >=3/week   1.52 (1.23, 1.89)  1.36 (0.85, 2.19)  
    
Portions of red meat eaten per week
†
     
None    1  <0.001 1 <0.001 
1-3  0.79 (0.72, 0.87 )  0.68 (0.55, 0.85)  
4 or more  0.61 (0.54, 0.68)
  
 0.48 (0.35, 0.65)  
Portions of fruit and veg eaten per day
†
     
<=2  1  <0.001 1 0.01 
3-5  1.21 (1.08, 1.37 )  1.11 (0.84, 1.48)  
More than 5  1.45 (1.26, 1.67)
  
 1.40 (1.02, 1.92)  
Number of visit to doctors in last 12mths
†
     
None 1  <0.001 1 0.9 
1-4 1.27 (1.12, 1.42 )  0.98 (0.76, 1.25)  
>4  1.45 (1.26, 1.67)
  
 0.98 (0.72, 1.33)  
Number of visit to alternative practitioner 
in last 12mths
†
 
    
None 1  <0.001 1 <0.001 
1-4 1.41 (1.23, 1.61 )  1.77 (1.35, 2.31)  
>4 1.75 (1.51, 2.03) 
 
 2.84 (2.20, 3.66)  
Number of participants in the models  10161 
 
 10161  
*Mutually adjusted for the other variables listed above, OR =Odds ratio 
† p for trend given 
 
Table 2 Odds ratio of taking supplements containing vitamin C: any dose; or 1000mg or more 
for UKWCS women who self-reported a personal or a family history of cancer  
  Any Dose(y/n): N=4242 (34%) >=1000mg(y/n): N =579 (5%) 
  Unadjusted Adjusted
*
 Unadjusted Adjusted
*
 
Type of cancer n
†
 OR(95% CI) OR(95% CI) OR(95% CI) OR(95% CI) 
Personal History       
      
Any cancer 1268 1.14 (1.01, 1.29) 1.12 (0.97, 1.28) 1.31 (1.02, 1.68) 1.33  (1.00,1.76) 
      
Any hormone 642   1.11 (0.94, 1.31) 1.08 (0.89, 1.31) 1.50 (1.09, 2.08) 1.68 (1.16, 2.43) 
      
Breast 523 1.13 (0.94,1.36) 1.10 (0.89, 1.35) 1.53 (1.08, 2.18) 1.70 (1.14, 2.55) 
Uterus 75 0.85 (0.52, 1.39) 0.77 (0.44, 1.34) 1.78 (0.77, 4.12) 1.97 (0.77, 5.02) 
Ovarian 60 1.29 (0.77, 2.17)    1.28 (0.71, 2.33) 1.35 (0.60, 3.07) 0.84 (0.20, 3.51) 
      
Any non-hormone 
cancer 
584 1.16 (0.98, 1.40) 1.11 (0.91, 1.34) 1.16 (0.80, 1.70) 1.05 (0.68, 1.60) 
Skin 324 1.14 (0.91, 1.43) 1.04 (0.81, 1.34) 0.85 (0.48, 1.49) 0.71 (0.36, 1.39) 
Cervix 190 1.26 (0.94, 1.69) 1.20 (0.86, 1.66) 2.03 (1.22, 3.36) 1.70 (0.94, 3.05) 
Colon Rectum 63 1.19 (0.71, 1.98) 1.30 (0.73, 2.30) 1.07 (0.34, 3.44) 0.98 (0.24, 4.10) 
      
Family history       
      
 Any cancer   7,259 1.08 (1.00, 1.16) 1.04 (0.96, 1.13) 1.15 (0.97, 1.36) 1.16 (0.95, 1.41) 
      
Any hormone cancer 3,629 1.09 (1.01, 1.18) 1.09 (0.99, 1.19) 1.16 (0.97, 1.38) 1.19 (0.98, 1.46) 
      
Breast 2,370 1.06 (0.97, 1.17) 1.04 (0.94, 1.16) 1.23 (1.00, 1.51) 1.26 (1.01, 1.58) 
Prostate 958 1.09 (0.95, 1.25) 1.13 (0.97, 1.32) 1.04 (0.76, 1.41) 1.09 (0.77, 1.51) 
Ovarian 423 1.10 (0.90, 1.35) 1.12 (0.90, 1.41) 1.07 (0.69, 1.70) 1.09 (0.66, 1.79) 
Uterus 380 1.41 (1.14, 1.73) 1.38 (1.10, 1.74) 1.08 (0.68, 1.73) 1.11 (0.66, 1.87) 
      
Any non-hormone 5,227 1.07 (0.99, 1.16) 1.03 (0.95,1.12) 1.03 (0.87, 1.22) 1.04 (0.86, 1.25) 
      
Lung 2,066 1.06 (0.96, 1.17) 1.00 (0.89, 1.11) 1.07 (0.86, 1.33) 1.00 (0.78, 1.29) 
Colon/Rectum 1,608 0.96 (0.86, 1.08) 0.98 (0.86, 1.11) 0.97 (0.76, 1.25) 1.08 (0.82, 1.43) 
Stomach 1,300 1.02 (0.90, 1.15) 1.01 (0.88, 1.16) 0.91 (0.69, 1.21) 0.97 (0.71, 1.33) 
Skin 957 1.01 (0.88, 1.16) 0.97 (0.83, 1.13) 0.88 (0.64, 1.23) 0.86 (0.60, 1.24) 
Pancreas 455 1.13 (0.93, 1.37) 1.11 (0.90, 1.38) 1.41 (0.96, 2.08) 1.44 (0.94, 2.21) 
Cervix 311 1.03 (0.81, 1.31) 1.04 (0.79, 1.36) 0.68 (0.36, 1.28) 0.74 (0.38, 1.46) 
*
Adjusted for BMI, age, social class, marital status, children, smoking status, level of physical activity, low alcohol 
consumption, red meat portions, total fruit and vegetable portions. 
†
Total numbers with history of cancer  
Table 3 Odds ratios of taking supplements containing vitamin C for a range of doses for UKWCS women who self-reported a 
personal history of cancer or a family history of breast cancer  
 Regular vitamin C doses greater or equal to 
  250mg(y/n)  500mg(y/n)  1000mg(y/n)  2000mg(y/n) 
  OR(95% CI)
*
  OR(95% CI)
*
  OR(95% CI)
*
  OR(95% CI)
*
 
 n
†
 N=1,448 (12%) n
†
 N=1,195(10%) n
†
 N=579 (5%) n
†
 N==92(1%) 
Personal history          
         
Any cancer 159 1.06 (0.87, 1.30) 131 1.03 (0.83, 1.29) 74 1.33  (1.00,1.76) 19 2.86 (1.64, 4.98) 
         
Any hormone cancer 81 1.04 (0.79, 1.39) 69 1.08 (0.80, 1.46) 43 1.68 (1.16, 2.43) 12 3.50 (1.75, 7.01) 
         
Breast cancer 68 1.10 (0.81, 1.49) 56 1.09 (0.78, 1.52) 36 1.70 (1.14, 2.55) 8 2.36 (1.00, 5.56) 
Uterus 8 0.99 (0.45, 2.22) 8 1.25 (0.56, 2.78) 6 1.97 (0.77, 5.02) 3 8.64 (2.52, 29.6) 
Ovarian 7 0.50 (0.15, 1.62) 7 0.64 (0.20, 2.06) 3 0.84 (0.20, 3.51) 1 2.75 (0.37, 20.8) 
         
Any non-hormone cancer  69 0.98 (0.73, 1.30) 56 0.97 (0.71, 1.33) 31 1.05 (0.68, 1.60) 8 2.52 (1.19, 5.32) 
         
Skin 34 0.79 (0.53, 1.20) 26 0.74 (0.47, 1.19) 13 0.71 (0.36, 1.39) 2 1.08 (0.26, 4.49) 
Cervix 32 1.43 (0.93, 2.21) 29 1.60 (1.03, 2.52) 17 1.70 (0.94, 3.05) 4 3.14 (1.10, 8.94) 
Colon Rectum 5 0.69 (0.24, 1.94) 3 0.41 (0.10, 1.72) 3 0.98 (0.24, 4.10) 2 7.20 (1.62, 32.1) 
         
Family history of breast cancer          
         
Any family member 299 1.15 (0.99, 1.34) 244 1.10 (0.93, 1.30) 129 1.26 (1.01, 1.58) 27 1.69 (1.01, 2.83) 
         
Mother or sister 163 1.13 (0.93, 1.37) 129 1.04 (0.84, 1.29) 67 1.16 (0.87, 1.55) 15 1.55 (0.81, 2.96) 
Respondent at raised risk 32 1.11 (0.73, 1.68) 25 1.04 (0.66, 1.65) 15 1.31 (0.73, 2.32) 4 2.03 (0.62, 6.56) 
Respondent at high risk 
‡
 9 0.67 (0.30, 1.47) 8 0.71 (0.31, 1.65) 4 0.69 (0.22, 2.23)   
         
*
Adjusted for BMI, age, social class, marital status, children, smoking status, level of physical activity, low alcohol consumption,  red meat portions, total fruit 
and vegetable portions. Comparison group = all respondents not taking stated dose. 
†
Total numbers with a history of cancer listed  taking doses specified. 
‡
Insufficient numbers at higher doses . 
 
Table 4 Odds ratios of taking supplements containing vitamin C: any dose; or 1000mg or more 
for UKWCS women who self-reported a family history or personal history of other illnesses 
  Any dose >=1000mg(y/n) 
  Unadjusted Adjusted
*
 Unadjusted Adjusted
*
 
Type of illness n OR(95% CI) OR(95% CI) OR(95% CI) OR(95% CI) 
Personal history      
      
CVD related disorders 3,217 0.90 (0.83, 0.98) 0.98 (0.89, 1.09) 1.00 (0.83, 1.21) 1.27 (1.02, 1.59) 
      
Heart attack 176 0.83 (0.60, 1.15) 0.90 (0.62, 1.30) 1.22 (0.64, 2.33) 1.63 (0.81, 3.30) 
Angina 293 0.90 (0.70, 1.15) 1.07 (0.81, 1.41) 1.42 (0.88, 2.29) 2.05 (1.21, 3.45) 
Stroke 172 1.15 (0.84, 1.57) 1.13 (0.79, 1.60) 1.13 (0.58, 2.23) 1.50 (0.72, 3.11) 
High bp 2,302 0.88 (0.80, 0.97) 0.97 (0.87, 1.09) 0.96 (0.77, 1.19) 1.20 (0.93, 1.54) 
High cholesterol 1,246 0.99 (0.88, 1.12) 1.07 (0.92, 1.23) 0.98 (0.74, 1.29) 1.19 (0.86, 1.64) 
Diabetes 265 0.64 (0.48, 0.84) 0.71 (0.51, 0.98) 0.47 (0.21, 1.06) 0.62 (0.25, 1.53) 
      
Gallstones 748 0.97 (0.83, 1.13) 1.00 (0.83, 1.19) 0.96 (0.68, 1.37) 1.04 (0.69, 1.57) 
      
Intestine disorders 4,716 1.21 (1.12, 1.30) 1.23 (1.13, 1.34) 1.22 (1.03, 1.45) 1.25 (1.03, 1.51) 
      
Polyps 179 0.88 (0.64, 1.21) 0.93 (0.65, 1.33) 0.83 (0.39, 1.80) 1.02 (0.44, 2.34) 
Stomach ulcer   941 1.17 (1.02, 1.34) 1.20 (1.02, 1.39) 1.02 (0.75, 1.39) 1.14 (0.82, 1.61) 
IBS 1,650 1.30 (1.17, 1.44) 1.31 (1.16, 1.47) 1.27 (1.01, 1.60) 1.27 (0.98, 1.64) 
Haemorrhoids 2,716 1.08 (0.99, 1.18) 1.07 (0.97, 1.19) 1.23 (1.01, 1.49) 1.26 (1.01, 1.56) 
Ulcerative colitis 140 0.98 (0.69, 1.40) 1.05 (0.69, 1.58) 1.07 (0.50, 2.30) 1.07 (0.43, 2.65) 
Diverticular    453 0.88 (0.72, 1.08) 0.97 (0.77, 1.22) 0.69 (0.41, 1.16) 0.65 (0.33, 1.28) 
Anal fissure 561 1.20 (1.01, 1.43) 1.17 (0.96, 1.43) 1.29 (0.89, 1.85) 1.41 (0.95, 2.09) 
      
Arthritis 3,391 1.20 (1.10, 1.30) 1.32 (1.19, 1.45) 0.97 (0.80, 1.17) 1.17 (0.93, 1.47) 
      
Family history      
      
CVD related disorders 9,765 1.03 (0.94, 1.12) 1.01 (0.91, 1.12) 1.20 (0.97, 1.48) 1.24 (0.96, 1.59) 
      
Heart attack 5,558 1.05 (0.97, 1.13) 1.06 (0.97, 1.15) 1.12 (0.95, 1.32) 1.11 (0.92, 1.34) 
Angina 2,982 0.97 (0.89, 1.06) 0.95 (0.86, 1.05) 1.20 (0.99, 1.45) 1.12 (0.91, 1.38) 
Stroke 3,799 1.04 (0.96, 1.13) 1.00 (0.91, 1.09) 0.93 (0.77, 1.12) 0.88 (0.72, 1.09) 
High bp 4,358 1.05 (0.97, 1.13) 1.03 (0.94, 1.12) 1.29 (1.09, 1.53) 1.30 (1.07, 1.57) 
High cholesterol 1,185 1.13 (0.99, 1.28) 1.16 (1.01, 1.33) 1.21 (0.93, 1.58) 1.21 (0.90, 1.61) 
Diabetes 2,320 1.01 (0.92, 1.11) 1.03 (0.92, 1.14) 1.07 (0.87, 1.33) 1.13 (0.90, 1.43) 
      
Intestine disorders 3,102 1.07 (0.98, 1.17) 1.07 (0.97, 1.18) 0.99 (0.81, 1.20) 1.00 (0.81, 1.24) 
      
Polyps 295 1.12 (0.88, 1.42) 1.09 (0.83, 1.42) 0.64 (0.33, 1.25) 0.50 (0.22, 1.14) 
Stomach ulcer 1,821 1.05 (0.94, 1.16) 1.03 (0.92, 1.16) 0.90 (0.71, 1.15) 0.90 (0.69,1.19) 
IBS 1,007 1.06 (0.93, 1.22) 1.10 (0.94, 1.28) 1.23 (0.93, 1.63) 1.34 (0.99, 1.82) 
Ulcerative 
colitis 
324 0.99 (0.79, 1.26) 0.99 (0.76, 1.28) 1.07 (0.64, 1.78) 1.27 (0.75, 2.18) 
Anal fissure 221 1.31 (1.00, 1.72) 1.30 (0.96, 1.75) 0.67 (0.31, 1.42) 0.53 (0.21, 1.29) 
      
Arthritis 5,165 1.20 (1.12, 1.30) 1.19 (1.10, 1.30) 1.12 (0.95, 1.33) 1.09 (0.90, 1.31) 
*
Adjusted for BMI, age, social class, marital status, no children, smoking status, level of physical activity, low 
alcohol consumption, red meat portions, total fruit and vegetable portions. 
CDV= cardiovascular disease 
IBS= Irritable bowel syndrome 
bp=blood pressure 
 
 
 
